Report

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

+ See all authors and affiliations

Science  31 Oct 2003:
Vol. 302, Issue 5646, pp. 875-878
DOI: 10.1126/science.1087061

You are currently viewing the abstract.

View Full Text

Abstract

Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clinical immunosuppression. We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolongedsurvival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants. CP-690,550 treatment was not associatedwith hypertension, hyperlipidemia, or lymphoproliferative disease. On the basis of these preclinical results, we believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation andin other clinical settings.

View Full Text